LivaNova (LIVN) Aandelenoverzicht
LivaNova PLC, een medisch technologiebedrijf, ontwerpt, ontwikkelt, produceert, verkoopt en verkoopt producten, therapieën en diensten in de Verenigde Staten, het Verenigd Koninkrijk, Duitsland, Frankrijk, Italië, Nederland, Spanje, België, Polen, Zweden, Zwitserland, Oostenrijk, Noorwegen, Portugal, Finland, Denemarken en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
LIVN onze risicocontroles hebben doorstaan.
LIVN Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LivaNova PLC Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$78.50 |
| 52 Week Hoogtepunt | US$80.96 |
| 52 Week Laag | US$41.02 |
| Bèta | 0.88 |
| 1 maand verandering | 8.68% |
| 3 maanden verandering | 23.56% |
| 1 Jaar Verandering | 73.79% |
| 3 jaar verandering | 55.78% |
| 5 jaar verandering | -8.78% |
| Verandering sinds IPO | 554.17% |
Recent nieuws en updates
Narratiefupdate • Jun 12
LIVN: Sleep Apnea Trial Progress And PMA Win Support Balanced 2026 Outlook
Analysts have nudged their price target on LivaNova higher by $3, reflecting updated assumptions around fair value, discount rate, and future P/E expectations. What's in the News The journal Annals of Internal Medicine published 12-month data from LivaNova's OSPREY randomized controlled trial, covering safety and efficacy of proximal hypoglossal nerve stimulation using the aura6000 System for moderate to severe obstructive sleep apnea, supporting clinically significant improvements in apnea metrics and patient-reported outcomes.Seeking Alpha • Jun 11
LivaNova: My Targets Hold, Maintaining My Rating For H2
Summary LivaNova remains a 'HOLD' with a maintained $68/share price target, reflecting cautious optimism amid recent outperformance. Recent double-digit AEPS and revenue growth are offset by margin compression, segment mix concerns, and a lack of dividend support. Valuation appears stretched above 15x P/E, with historical cycles of overvaluation and subsequent normalization limiting near-term upside. LIVN's risks include slowing neuromodulation growth, unproven new products, and reliance on currency effects rather than organic demand. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Jun 12
LIVN: Sleep Apnea Trial Progress And PMA Win Support Balanced 2026 Outlook
Analysts have nudged their price target on LivaNova higher by $3, reflecting updated assumptions around fair value, discount rate, and future P/E expectations. What's in the News The journal Annals of Internal Medicine published 12-month data from LivaNova's OSPREY randomized controlled trial, covering safety and efficacy of proximal hypoglossal nerve stimulation using the aura6000 System for moderate to severe obstructive sleep apnea, supporting clinically significant improvements in apnea metrics and patient-reported outcomes.Seeking Alpha • Jun 11
LivaNova: My Targets Hold, Maintaining My Rating For H2
Summary LivaNova remains a 'HOLD' with a maintained $68/share price target, reflecting cautious optimism amid recent outperformance. Recent double-digit AEPS and revenue growth are offset by margin compression, segment mix concerns, and a lack of dividend support. Valuation appears stretched above 15x P/E, with historical cycles of overvaluation and subsequent normalization limiting near-term upside. LIVN's risks include slowing neuromodulation growth, unproven new products, and reliance on currency effects rather than organic demand. Read the full article on Seeking AlphaNarratiefupdate • May 29
LIVN: 2026 Outlook Balances Sleep Apnea Progress With Execution And Margin Risks
Analysts have nudged their price target on LivaNova up by $1 to reflect updated assumptions around slightly higher revenue growth, a wider profit margin and a lower future P/E multiple, supported in part by recent Street research, including the $3 price target increase at Barclays. Analyst Commentary Bullish Takeaways Bullish analysts see the recent price target increase as consistent with expectations for steadier revenue contribution from LivaNova's existing portfolio, which they view as reasonably aligned with the updated assumptions on growth.Narratiefupdate • May 05
LIVN: 2026 Outlook And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova edges slightly lower to about $79.18 from $79.91, even as analysts point to recent Q4 strength, better than expected neuromodulation and cardiopulmonary results, and a solid 2026 outlook as support for their models. Analyst Commentary Recent Street research reflects a generally positive tone on LivaNova, with several firms lifting their price targets following Q4 results and updated 2026 commentary.
Narratiefupdate • Apr 20
LIVN: 2026 Core Execution And OSA Expansion Will Test Fair Value View
The analyst price target for LivaNova has been raised by a few dollars per share, with the higher range of $73 to $85 cited in connection with stronger recent results, a firmer 2026 outlook, and expectations for sustained contributions from neuromodulation and cardiopulmonary. Analyst Commentary Recent Street research on LivaNova clusters in a higher target range of about $73 to $85, with most analysts pointing to recent results, solid contributions from neuromodulation and cardiopulmonary, and management's 2026 outlook as key inputs to their updated models.Narratiefupdate • Apr 06
LIVN: 2026 Execution In Core Segments Will Test Fair Value View
Analysts have increased the blended price target for LivaNova by several dollars into the low to mid $70s, reflecting Q4 outperformance, constructive 2026 commentary, and updated models that indicate solid contributions from both neuromodulation and cardiopulmonary segments. Analyst Commentary Recent Street commentary around LivaNova clusters around upward revisions to price targets, but the tone is not uniformly bullish.Narratiefupdate • Mar 22
LIVN: 2026 Setup And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova rises from about $73 to roughly $80, reflecting analysts' responses to recent Q4 results, revised models for 2026, and supportive commentary on the company's neuromodulation and cardiopulmonary performance. Analyst Commentary Recent research updates show a cluster of higher price targets for LivaNova, with analysts focusing on Q4 performance, expectations for 2026, and the contribution from neuromodulation and cardiopulmonary.Narratiefupdate • Mar 08
LIVN: Fairly Valued As 2026 Outlook Offsets Multiple Compression Risk
The updated analyst price target for LivaNova moves from a fair value estimate of $56 to about $67. Analysts point to recent price target hikes across the Street that reference Q4 outperformance, solid 2026 commentary, and expectations for consistent organic growth as key supports for the revised view.
Narratiefupdate • Feb 22
LIVN: 2026 Organic Drivers And Medicare Shift Will Support Re Rating
Narrative Update on LivaNova LivaNova’s updated analyst price targets, rising by roughly $8 to $12 per share into the mid to high $60s and low $70s, reflect analysts’ use of higher target multiples in line with comparable MedTech names. They also indicate a view that organic growth will play a larger role in relative valuation from 2026 onward.Narratiefupdate • Feb 08
LIVN: Higher 2026 Medtech Multiples And Reimbursement Shift Will Drive Re Rating
Narrative Update on LivaNova LivaNova's analyst price targets have shifted higher into a roughly mid US$60s to US$70 range. Analysts point to adjusted target multiples that align more closely with comparable MedTech names and updated views on organic growth and sector setup into 2026.Narratiefupdate • Jan 25
LIVN: Improved Reimbursement And 2026 Reset Will Support Constructive Repricing
Narrative Update The analyst price target on LivaNova has been lifted from about US$69 to roughly US$73 as analysts factor in higher target multiples, in line with recent moves in comparable MedTech names and modestly more constructive views reflected in updated fair value, discount rate, revenue growth, profit margin and forward P/E assumptions. Analyst Commentary Recent research updates on LivaNova cluster around higher price targets and a reset in expectations for 2026, with most of the discussion focused on how the shares should trade relative to other MedTech names as fundamentals and valuation reconnect.Narratiefupdate • Jan 09
LIVN: Higher Medtech Multiples And Reimbursement Changes Will Support Re Rating
The analyst fair value estimate for LivaNova has moved from US$80 to US$86, reflecting analysts' use of higher target P/E multiples in line with recent moves in comparable MedTech names and updated views on revenue growth and profit margins. Analyst Commentary Bullish analysts are lifting their targets for LivaNova, pointing to higher target P/E multiples that are more in line with comparable MedTech peers.Narratiefupdate • Dec 26
LIVN: Higher Reimbursement Will Still Leave Shares Vulnerable To Multiple Compression
Analysts have modestly raised their price target on LivaNova to $56.00 per share. This reflects slightly stronger long term revenue growth and margin expectations, partially offset by a lower assumed future earnings multiple and a marginally higher discount rate.Narratiefupdate • Dec 12
LIVN: Improved Reimbursement And Raised Guidance Will Support Measured 2025 Outlook
Analysts have modestly revised their price target for LivaNova to remain effectively unchanged at approximately 69 dollars per share. This reflects stable assumptions around revenue growth, profitability, and valuation multiples, despite only incremental tweaks to the discount rate and long term earnings expectations.Analyseartikel • Dec 07
Improved Revenues Required Before LivaNova PLC (NASDAQ:LIVN) Stock's 26% Jump Looks Justified
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...Narratiefupdate • Nov 28
LIVN: Reimbursement Rate Increases And Guidance Raise Will Support 2025 Momentum
Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.Narratiefupdate • Nov 14
LIVN: Upgraded 2025 Outlook Will Drive Confidence Amid Business Momentum
Narrative Update on LivaNova Analyst Price Target Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.Analyseartikel • Aug 17
Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...Narratiefupdate • Aug 08
Aging Populations And China Expansion Will Drive Device Adoption
Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).Analyseartikel • Aug 03
LivaNova (NASDAQ:LIVN) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Jul 07
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Analyseartikel • Apr 11
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
LivaNova PLC's ( NASDAQ:LIVN ) price-to-earnings (or "P/E") ratio of 29.3x might make it look like a strong sell right...Analyseartikel • Mar 21
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it received a lot of attention from a...
Nieuw narratief • Mar 11
Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.Analyseartikel • Feb 28
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LivaNova PLC ( NASDAQ:LIVN ) shareholders, with the stock dropping 15% to US$40.93 in the...Analyseartikel • Feb 25
We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Dec 28
LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking
You may think that with a price-to-sales (or "P/S") ratio of 2x LivaNova PLC ( NASDAQ:LIVN ) is a stock worth checking...Analyseartikel • Nov 12
We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Even though LivaNova PLC ( NASDAQ:LIVN ) posted strong earnings, investors appeared to be underwhelmed. We did some...Analyseartikel • Nov 03
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
A week ago, LivaNova PLC ( NASDAQ:LIVN ) came out with a strong set of third-quarter numbers that could potentially...Analyseartikel • Oct 31
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Seeking Alpha • Oct 18
LivaNova: Economics Should Start Making Sustained Improvements
Summary LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. Despite potential liabilities from an Italian lawsuit, valuation looks compelling based on implied value of the DTD option, where they will decide on commercialization next year. Even outside the DTD growth opportunity, recurring economics and medical device industry margins suggest sustained improvements in economics coming. Read the full article on Seeking AlphaAnalyseartikel • Oct 02
Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Key Insights The projected fair value for LivaNova is US$76.07 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Aug 21
LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
LivaNova PLC's ( NASDAQ:LIVN ) price-to-sales (or "P/S") ratio of 2.1x might make it look like a buy right now compared...Analyseartikel • Jul 30
LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Analyseartikel • Jul 04
At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it saw significant share price movement during...Analyseartikel • Jun 13
Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?
Key Insights LivaNova's estimated fair value is US$76.63 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • May 12
LivaNova: Focus Is Paying Off
Summary LivaNova has streamlined operations and increased income by shutting down ANTHEM trials and releasing new, premium products. Operating margins have improved from 10% to 18% due to savings in R&D and the mix effects from Essenz. LIVN's epilepsy products are scaling, with new implants driving growth and a strong recurring revenue base. Capacity expansions are coming for oxygenators which will increase cardiopulmonary segment volumes starting next quarter. Remaining trials are promising yet are being given an implied negative options value, a testament to the existing businesses and also to the value case. Read the full article on Seeking AlphaRendement voor aandeelhouders
| LIVN | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 0.2% | -2.5% | 2.0% |
| 1Y | 73.8% | -21.4% | 23.3% |
Rendement versus industrie: LIVN overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -21.4 % opleverde.
Rendement versus markt: LIVN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 23.3 %.
Prijsvolatiliteit
| LIVN volatility | |
|---|---|
| LIVN Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: LIVN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van LIVN is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2015 | 3,300 | Vladimir Makatsaria | www.livanova.com |
LivaNova PLC, een medisch technologiebedrijf, ontwerpt, ontwikkelt, produceert, verkoopt en verkoopt producten, therapieën en diensten in de Verenigde Staten, het Verenigd Koninkrijk, Duitsland, Frankrijk, Italië, Nederland, Spanje, België, Polen, Zweden, Zwitserland, Oostenrijk, Noorwegen, Portugal, Finland, Denemarken en internationaal. Het bedrijf opereert in twee segmenten, Cardiopulmonair en Neuromodulatie. Het segment Cardiopulmonaire producten levert cardiopulmonaire producten, waaronder hart-longmachines, oxygenators, autotransfusiesystemen, perfusieslangsystemen, canules en andere gerelateerde accessoires, evenals aanverwante diensten.
LivaNova PLC Samenvatting
| LIVN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$4.37b |
| Inkomsten(TTM) | US$107.15m |
| Inkomsten(TTM) | US$1.43b |
40.2x
Koers/Winstverhouding3.0x
P/S-verhoudingIs LIVN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LIVN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.43b |
| Kosten van inkomsten | US$460.79m |
| Brutowinst | US$972.67m |
| Overige uitgaven | US$865.52m |
| Inkomsten | US$107.15m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.95 |
| Brutomarge | 67.85% |
| Nettowinstmarge | 7.47% |
| Schuld/Eigen Vermogen Verhouding | 23.8% |
Hoe presteerde LIVN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/17 19:36 |
| Aandelenkoers aan het einde van de dag | 2026/06/17 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
LivaNova PLC wordt gevolgd door 24 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Rescott | Baird |
| Matthew Miksic | Barclays |
| Scott Bardo | Berenberg |